Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489387 | 1.00 | HTT (0.45) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1503218 | 0.80 | PIK3CA (0.45) | HTTALDH1A1DAOMAOBTTR | |
| SCHEMBL28204423 | 0.80 | TTR (0.34) | HTTALDH1A1TTR | |
| SCHEMBL26568588 | 0.80 | DAO (0.44) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL31634179 | 0.80 | MAPT (0.42) | TTR | |
| SCHEMBL4524759 | 0.80 | MAPT (0.42) | TTR | |
| SCHEMBL6744483 | 0.78 | CYP17A1 (0.44) | ALDH1A1CYP17A1CYP11B1CYP11B2TTR | |
| SCHEMBL6744478 | 0.78 | CA1 (0.34) | HTTALDH1A1RIPK1TTR | |
| SCHEMBL15912481 | 0.78 | KDM1A (0.37) | KDM1ATTR | |
| SCHEMBL8951118 | 0.78 | DAO (0.43) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307768-B | Quinolone derivative and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2023-12-12 | — | — | CN | claimed |
| CN-103996872-A | Lithium ion battery non-aqueous electrolyte with functions of overcharging prevention and flame retardancy | ZHUHAI SMOOTHWAY ELECTRONIC MATERIALS CO LTD | 2014-08-20 | — | — | CN | claimed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-113307768-B | Quinolone derivative and preparation method and application thereof | 中国农业科学院兰州畜牧与兽药研究所 | 2023-12-12 | — | — | CN | disclosed |
| CN-114516837-B | Nuciferine derivative, and preparation method and application thereof | 山东师范大学 | 2023-11-28 | — | — | CN | disclosed |
| EP-0391186-A1 | Nitro substituted benzotiazolones, process for their production and their use as pesticides and new intermediates | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
| US-4536599-A | HYDROLYZING THE NITRILE DERIVATIVE TO THE AMIDE USING AN ORGANIC QUATERNARY AMINE SALT CATALYST; EFFICIENCY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0008532-B1 | SYNTHESIS OF AMINES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| EP-0008532-A1 | Synthesis of amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-03-05 | — | — | EP | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3932452-A | 1-Arylmethyl-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | HTT 4818/4885ALDH1A1 1195/4885CYP17A1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.